oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides

FEMS Immunology and Medical Microbiology

Volumn 60, Issue 3, 2010, Pages 275-282

  Wang, Hui ^a   Meng, Jingru ^a   Jia, Min ^a   Ma, Xue ^a   He, Gonghao ^a   Yu, Jichen ^b   Wang, Rutao ^b   Bai, Hui ^a   Hou, Zheng ^a   Luo, Xiaoxing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Xi'an Libang Pharmaceuticals CoLtd   (China)

Author keywords

Anionic liposome; Antibiotics resistance; Multidrug resistant Pseudomonas aeruginosa (MDR PA); Phosphorothioate oligodeoxynucleotides (PS ODNs)

Indexed keywords

AMIKACIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; CEFOPERAZONE; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; LIPOSOME; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PIPERACILLIN; POLYETHYLENEIMINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; CONCENTRATION RESPONSE; ENCAPSULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OPRM GENE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION; HUMANS; LIPOSOMES; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PIPERACILLIN; POLYETHYLENEIMINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 78349267905     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00742.x     Document Type: Article

References (30)

1. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S & Carmeli Y (2006) Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Ch 50: 43-48.
2. Bianco N, Neshat S & Poole K (1997) Conservation of the multidrug resistance efflux gene oprM in Pseudomonas aeruginosa. Antimicrob Agents Ch 41: 853-856.
3. Boutoille D, Jacqueline C, Le Mabecque V, Potel G & Caillon J (2009) In vivo impact of the MexAB-OprM efflux system on β-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection. Int J Antimicrob Ag 33: 417-420.
4. Carmeli Y, Troillet N, Karchmer AW & Samore MH (1999) Health and economic outcomes of antibiotic resistant Pseudomonas aeruginosa. Arch Intern Med 159: 1127-1132.
5. Chen T, Wang Z, Wang R, Lu T & Wang W (2007) Polyethylenimine DNA solid particles for gene delivery. J Drug Target 15: 714-720.
6. D'Agata EM (2004) Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect Cont Hosp Ep 25: 842-846.
7. Gao MY, Xu CR, Chen R, Liu SG & Feng JN (2005) Chloromycetin resistance of clinically isolated E. coli is conversed by using EGS technique to repress the chloromycetin acetyl transferase. World J Gastroentero 11: 7368-7373.
8. Geller BL (2005) Antibacterial antisense. Curr Opin Mol Ther 7: 109-113.
9. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock RE & Speert DP (2002) Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 196: 109-118.
10. Hocquet D, Roussel-Delvallez M, Cavallo JD & Plésiat P (2007) MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob Agents Ch 51: 1582-1583.
11. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR & Sahm DF (2003) Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Ch 47: 1681-1688.
12. Li XZ, Nikaido H & Poole K (1995) Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob Agents Ch 39: 1948-1953.
13. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H & Nishino T (2000a) Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Ch 44: 2242-2246.
14. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H & Nishino T (2000b) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Ch 44: 3322-3327.
15. Meng JR, Wang H, Hou Z, Chen T, Fu JG, Ma X, He GH, Xue XY, Jia M & Luo X (2009) The novel anion liposome encapsulated antisense oligonucleotide restores susceptibility of MRSA and rescues mice from lethal sepsis by targeting mecA. Antimicrob Agents Ch 53: 2871-2878.
16. Muzzi A, Masignani V & Rappuoli R (2007) The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov Today 12: 429-439.
17. Obritsch MD, Fish DN & MacLaren Jung R (2004) National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Ch 48: 4606-4610.
18. Obritsch MD, Fish DN, MacLaren R & Jung R (2005) Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25: 1353-1364.
19. Ohmagari N, Hanna H, Graviss L et al. (2005) Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104: 205-212.
20. Payne DJ (2008) Microbiology. Desperately seeking new antibiotics. Science 321: 1644-1645.
21. Poole K, Krebes K, McNally C & Neshat S (1993) Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 175: 7363-7372.
22. Sarno R, Ha H, Weinsetel N & Tolmasky ME (2003) Inhibition of aminoglycoside 60-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides. Antimicrob Agents Ch 47: 3296-3304.
23. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ & Reed MW (2000) Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 285: 194-204.
24. Srikumar R, Tsang E & Poole K (1999) Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa. J Antimicrob Chemoth 44: 537-540.
25. Taylor PW, Stapleton PD & Paul Luzio J (2002) New ways to treat bacterial infections. Drug Discov Today 7: 1086-1091.
26. Torres Viera C, Tsiodras S, Coakley EP, Wennersten C, Eliopoulos GM, Moellering RC Jr & Inouye RT (2001) Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer. Antimicrob Agents Ch 45: 973-975.
27. White DG, Maneewannakul K, Zillman M, Eisenberg W, Field AK & Levy SB (1997) Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs. Antimicrob Agents Ch 41: 2699-2704.
28. Winer J, Jung CK, Shackel I & Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270: 41-49.
29. Woodford N, Wareham DW & UK Antibacterial Antisense Study Group (2009) Tackling antibiotic resistance: a dose of common antisense? J Antimicrob Chemoth 63: 225-229.
30. Ziha-Zarifi I, Llanes C, Köhler T, Pechere JC & Plesiat P (1999) In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Ch 43: 287-291.